$NVO $lly This is potency data from Eloralintide and zenagamtide early publications. Both molecules were compared to cagrilintide in their respective papers, the cross-paper fold relationships hold to within a factor of ~2x.
So cagrilintide and petrelintide look pretty similar on this basis
I have been wondering why zena appears so uniquely toxic. Zenagamtide has low potency overall at any ctr family receptor and is the least selective between amyr1 and ctr. But it has full potency at glp-1. Probably part of why its so toxic, they are hitting glp-1 so hard to get a small amyr1 benefit? Besides the short t1/2 (3.5 days) which also means I have to acutely spike the concentration to get sufficient coverage for the week. I also wonder what the effect is of having a single large molecule as opposed to cagrilintide+semaglutide which can distribute differently.
Basically every single thing about this peptide seems badly designed.
Occam’s R̶e̶t̶a̶r̶d̶ Highly Regarded Allocator of retweeted
I can not quote tweet b/c he blocked me, but you should notice he put the words “accelerate” and “rapid” and “radically cut timelines” in his post. It’s been 5+ years. Your timelines are behind schedule especially for your funding.
There is nothing accelerated or rapid about Isomorphic’s progress in 5+ years. They do not have any human studies or even any specific preclinical data.
Milestone: Hassabis, Max and staff are able to sell a lot on the Secondaries though, so I guess that’s good for them.
To everyone, who said I’m dumb and they will def have human studies in 2026, there is “more to announce in 2027” and will be “hundreds of drugs”
Ok, why not just have 1 to start?
Im going full highly regarded allocator in $KLRA
1
1
773
Manufacturers can do a better job here too though. For one, start treating obesity like a real disease and glp-1 as a standard of care if that's supposed to be their message. Like stop running weight loss trials against placebo! And stop partnering with grifters like $HIMS and RO themselves who charge $75-150/mo just to write a script! That kind of rent-seeking is just unethical!
I think the insurance industry attitude towards obesity matters but at the same time, I am kind of opposed in general to socializing the cost of relatively affordable chronic medication vs letting the individual pay. Especially with glp-1s where there are immediate cost offsets like groceries (might seem trivial but is definitely not when considering the overall economics).
169
$NVO I'm not sure what unmet need they think they're addressing with this bone stuff. I'm only looking into this now so haven't in depth yet. But if it were an issue it should show up in fracture imbalances. Overall fractures if anything look less likely in the glp-1 group vs placebo. The most compelling would be an elevated rate in post menopausal women not on HRT (since estradiol plays an important role in bone health). Even in the SELECT subgroup where the imbalance shows up the absolute risk is low. And you see higher rate of hip+pelvis fractures but overall fractures unchanged.
The Evoke trials (mean age ~72) point to glp-1 being protective for bone and joint injuries.
And there are cheap generics that can address this if it is an issue (or put them on HRT if that's where it's showing up).
Similar shape as the muscle nonsense. Pretending they're addressing a problem without even proving it exists, or even when a lot of evidence points to the opposite being the case.
The below table is compiled from my library of clinical trial publications, plus some other data from a meta analysis pre print.
2
2
1,000
Occam’s R̶e̶t̶a̶r̶d̶ Highly Regarded Allocator of retweeted
Replying to @MichaelAlbertMD
Come on. You can't pretend like you are saying this because it's in the best interest of patients when you're trying to charge $90 for some useless supplements or $20 for a "field guide" pdf that you had Claude put together from the FDA labels.
$VGT undercutting the panic low from 11/5 🙈
104
$KLRA ceo talking doo doo on $VKTX and $pfe and others for these stupid varied dosing schemes 😂 "not a good use of our financial resources to prove what people can figure out for themselves." I said this previously, I like this CEO because he seems to focus on what matters. Just prove the thing is safe and effective and get it on the market. If someone wants to dose q2w or qm or standing on their heads in the shower, whatever, they will figure that out for themselves.
I do think vk2735 is a better molecule but ribu is a good molecule and vk CEO is frustrating because he talks too much about this dumb stuff that isn't what they should be focusing on to deliver value for shareholders.
Corollary to this imo it's a yellow flag when mgmt spends too much time and resources highlighting different dosing regimens etc (and that includes $VKTX stupid design of upcoming maint trial, as well as $pfe with their stupid monthly dosing gimmick). Focus on developing the best molecule and pricing it competitively and patients and practitioners will figure out how best to dose it in the real world.
2
13
2,920
Occam’s R̶e̶t̶a̶r̶d̶ Highly Regarded Allocator of retweeted
wtf, a rogue AI hacked my account and said this right at the low. Private discord bought 0dte calls and flipped them for big $$$$
Replying to @hcapinvesting
POV: I’m retarded
$KLRA Gemini-1 published so I could generate the cumulative dose-response curves. It looks a lot like tzp. 6mg should sit right on top of 15 mg tzp at 72 weeks if the male:female ratio was matched (G-1 was 54% F vs Surmount-1 68% F, which should make roughly a 1 pp difference). The sm-1 pbo group also ran 1pp ahead of g-1.
The separate 8 mg curve is smaller n = 49 and comparable Female % to typical western obesity trials.
$KLRA $LLY I've been looking more at placebo AE rates in glp-1 trials as a check on reporting standards. Looking at this ribupatide compared to Lilly's asian tzp trials. This is adjusted per patient year.
I know there's concern the results won't translate to a global population but when I look at the trends and think about how AEs and wl skew when going from asia to global, imo if anything they should be better in a global pop. All three terms (n,v,d) ran high in the ribu china placebo arm vs tzp asian trials and global pooled. I made some charts and tables to compare.
One thing, I hadn't realized previously that surmount-1 had really low rates of AEs compared to the later Surmount trials. The later trials are more consistent with each other. So if anything those are better bars for future glp/gips.
1
259
Dan you dumped your shi*coin $orbs or whatever it's called on all your retail followers right at the height of the stupid "crypto holding Co" bubble last year. You're a criminal. Same thing with your buddy Tom Lee and his ETH shitco.
No one individual can replace Jensen as CEO….but at the end of the day after this global scandal the old Jensen with the black leather jacket and rock star persona is gone for good….that cannot be replicated and any talk of a damaged Jensen coming back to Nvidia is ridiculous in our view given the legal/Board/DC scrutiny/moral compass/China tentacles. We see no chance Jensen comes back to Nvidia as CEO. It’s about moving forward for Nvidia and it starts Tuesday with earnings as Colette leads NVDA ahead (for now)
1
194
$LLY people were surprised at the AE rates from the eloraTZP data shared several weeks ago. It turns out the entire trial ran high on AEs compared to typical reporting patterns for similar trials in diabetics (using placebo and 15 mg tzp mono rates as a check). Also $NVO is not reporting any asthenia in some of their cagrisema t2d trials?
5
815
$NVO Cagrisema Redefine 9 AEs overall incredibly bad LOL no wonder they were hiding it. I included the terms from Redefine 1 as well for reference. So 1/1 and 1.7/1.7 both much WORSE than we saw in redefine 1 hence why they didn't brag about tolerability
$NVO still being tight-lipped on AEs from Redefine 9 (locked behind hard to access lancet D&E til clinical key updates) but at least now we know EE and TRE reverse between the 1/1 and 1.7 doses, consistent with no improvement in tolerability at the lower dose and actual observed worse tolerability at 1/1 in this particular instance.
Direct quote from my below post:
"On AEs and tolerability with CS, my guess they might not have seen much if any improvemen when reducing from 2.4 to 1.0, which is a general trend with amylins, and explains why they haven't shown an AE table, because if there were an improvement it would be something to brag about. In redefine 1 only <60% of those assigned to 2.4/2.4 finished on it, but those who stepped back down are pretty uniformly distributed across the lower doses, which also hints at no monotonic improvement in tolerability unlike how you see with sema 2.4."


























